Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

This page covers all Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds.

Marketed (7)

• Biktarvy · Gilead Sciences · Immunology · 13400
  Biktarvy works by binding to the integrase enzyme, preventing the HIV virus from integrating its genetic material into the host cell's DNA.
• Vemlidy · Gilead Sciences · Immunology · 2800
  Vemlidy works by inhibiting the HIV reverse transcriptase enzyme, preventing viral replication.
• Emtriva · Gilead Sciences · Immunology · 2400
  Emtriva works by blocking the reverse transcriptase enzyme, which is necessary for HIV to replicate.
• BICTEGRAVIR SODIUM
• Ziagen · GSK · Immunology
  Abacavir works by mimicking a building block of DNA, tricking the virus into incorporating it into its genetic material and preventing replication.
• Videx · Bristol-Myers Squibb · Immunology
• TENOFOVIR ALAFENAMIDE FUMARATE

Patent intelligence

• human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates